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AbsTrACT
Objective to evaluate clinical, interferon and imaging 
predictors of progression from ’At risk’ to autoimmune 
connective tissue diseases (AI-Ctds).
Methods A prospective observational study was 
conducted in At-risk of AI-Ctd (defined as antinuclear 
antibody (AnA) positive; ≤1 clinical systemic lupus 
erythematosus (SLE) criterion; symptom duration <12 
months and treatment-naïve). Bloods and skin biopsy 
(non-lesional) were analysed for two interferon-
stimulated gene expression scores previously described 
(IFn-Score-A and IFn-Score-B). Forty-nine healthy 
controls (HCs) and 114 SLE were used as negative 
and positive controls. Musculoskeletal ultrasound 
was performed. progression was defined by meeting 
classification criteria for AI-Ctds at 12 months.
results 118 individuals with 12-month follow-up 
were included. of these, 19/118 (16%) progressed to 
AI-Ctd (SLE=14, primary Sjogren’s=5). At baseline, 
both IFn scores differed among At-risk, HCs and SLE 
groups (p<0.001) and both were elevated in At-risk 
who progressed to AI-Ctd at 12 months versus non-
progressors, to a greater extent for IFn-Score-B (fold 
difference (95% CI) 3.22 (1.74 to 5.95), p<0.001) than 
IFn-Score-A (2.94 (1.14 to 7.54); p=0.018). progressors 
did not have significantly greater baseline clinical 
characteristics or ultrasound findings. Fold difference 
between At-risk and HCs for IFn-Score-A was markedly 
greater in skin than blood. In multivariable logistic 
regression, only family history of autoimmune rheumatic 
disease, or 8.2 (95% CI 1.58 to 42.53) and IFn-Score-B, 
3.79 (1.50–9.58) increased the odds of progression.
Conclusion A two-factor interferon score and family 
history predict progression from AnA positivity to AI-
Ctd. these interferon scores may allow stratification 
of individuals At-risk of AI-Ctd permitting early 
intervention for disease prevention and avoid irreversible 
organ damage.
InTrOduCTIOn
Autoimmune connective tissue diseases (AI-CTDs) 
include systemic lupus erythematosus (SLE), 
primary Sjogren’s syndrome (pSS), systemic scle-
rosis, inflammatory myopathies, mixed and undif-
ferentiated CTDs. A hallmark of their pathogenesis 
is loss of self-tolerance leading to autoreactivity 
and production of antibodies against self-nuclear 
antigens (ANAs). ANA can be detected in serum up 
to 10 years before clinical features, representing a 
phase of subclinical autoimmunity.1 However, ANA 
is present in up to 25% of the general population, 
of whom less than 1% develop clinical autoimmu-
nity.2 3 Individuals with ANA therefore constitute 
At-Risk population of whom a minority will prog-
ress to AI-CTD.4 5 The factors that dictate whether 
this autoreactivity develops into autoimmune 
disease are unknown. But if these were understood 
and predictable, then effective intervention might 
be possible, preventing the severe disease and heavy 
glucocorticoid use for remission induction of a 
newly diagnosed AI-CTD.
Variants in type I interferon (IFN-I) pathway 
are prominent in the genetic susceptibility to 
AI-CTDs and therefore a focus for investiga-
tion.6–8 However, their role in disease initiation is 
currently unclear. IFN activity is usually quantified 
using expression of interferon-stimulated genes 
(ISGs). Interpretation of ISG expression is complex 
with multiple IFN subtypes produced by different 
cell types and tissues, as well as a transcriptional 
response in all nucleated cells with variation 
between cell types. Previously used IFN signatures 
have a categorical high/low classification9 10 or 
may have been affected by the ISGs selected.11–13 
We recently described two continuous ISG expres-
sion scores (IFN-Score-A and IFN-Score-B) that in 
combination better identify clinically meaningful 
differences in IFN status between and within auto-
immune diseases.14
In other autoimmune diseases such as rheuma-
toid arthritis (RA), early evidence of progression to 
disease may be found at a target tissue level.15 The 
tissues most commonly affected in AI-CTDs are 
the joints and skin. Musculoskeletal ultrasound can 
detect subclinical synovitis in SLE16 but has not been 
assessed in At-Risk individuals. In skin, specialised 
local immune processes are found in SLE. Previous 
studies comparing keratinocytes or skin biopsies 
isolated from patients with cutaneous lupus and 
healthy controls (HCs) found marked differences 
in IL-18R responsiveness,17 IFN-λ expression,18 as 
well as a role of IFN-κ in initiating a feed-forward 
loop, which promoted exaggerated ISG activation 
in cutaneous lupus.19 IFN-I status in the skin has 
not been assessed in At-Risk individuals.
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The aims of this study were to evaluate clinical, blood and 
tissue interferon and imaging biomarkers of progression from 
At-Risk to AI-CTD with a view to establish a strategy for disease 
prevention.
MeTHOds
Patients and design
A prospective observational study was undertaken in individuals 
who were referred from primary care to Leeds Teaching Hospi-
tals NHS Trust due to suspected AI-CTD between November 
2014 and May 2017. Inclusion criteria were (1) ANA-positive 
of at least 1:80 titre on indirect immunofluorescence and using 
multiplex immunoassays (excluding those with scleroderma 
(centromere, Scl-70) or myositis-specific (PL-12, OJ, PL-7, Mi-2, 
Ku, Jo-1, PM-Scl75, PM-Scl100, SRP and EJ) antibodies only); 
(2) ≤1 clinical criterion based on 2012 Systemic Lupus Inter-
national Collaborating Clinics Classification Criteria (SLICC)20 
and not meeting classification criteria for other AI-CTD21–23 or 
RA24; (3) symptom duration <12 months; (4) glucocorticoid, 
antimalarial and immunosuppressive treatment-naïve. Forty-
nine HCs and 114 patients with SLE were used as negative and 
positive controls.
Assessment schedule and outcome
Comprehensive assessments including clinical, laboratory, 
imaging, bloods and skin biomarkers were performed at base-
line, 12 months and annually for 3 years. Participants were given 
a helpline number for an additional flare visit if they had new or 
worsening inflammatory symptoms. Progression was defined by 
meeting the 2012 SLICC criteria for SLE,20 2016 ACR/EULAR 
criteria for pSS21 or other relevant classification criteria for 
AI-CTD22 23 at 12 months as assessed by rheumatologists.
Clinical and laboratory assessment
Age, gender, ethnicity, history of first-degree or second-de-
gree relative(s) with autoimmune rheumatic diseases (ARDs), 
smoking history, SLICC criteria for SLE,20 signs or glandular 
symptoms criteria for pSS,21 patient and physician global health 
assessment using 100 mm Visual Analogue Scale were recorded.
ANA was tested using indirect immunofluorescence and a 
panel of nuclear autoantibodies including anti-dsDNA, extract-
able nuclear antigens (including Ro52, Ro60, La, Sm, Chro-
matin, RNP, Sm/RNP and Ribosomal P) and antiphospholipid 
antibodies (Cardiolipin and B2-Glycoprotein IgGs) using Bioplex 
2200 Immunoassay. Lupus anticoagulant tests including acti-
vated partial thromboplastin time (APTT) (Actin FS), APTT-syn-
thetic phospholipid (with correction) and dilute Russell's viper 
venom time (with correction) were deemed positive if persistent 
when repeated at 12 weeks. Full blood count was processed at a 
single accredited diagnostic laboratory. Complement levels (C3 
and C4) were measured by nephelometry.
Musculoskeletal ultrasound
Ultrasound examination of wrists, metacarpophalangeal and 
proximal interphalangeal joints were performed by two rheu-
matologists, using General Electric S7 machine with a 6–15 
MHz transducer. Outcome Measures in RA Clinical Trials 
(OMERACT) criteria25 were used to define synovitis, that is, 
the presence of grey-scale (GS) ≥grade 2 and/or power Doppler 
(PD) ≥grade 1.
blood and skin IFn scores
A two-score system of ISGs, as previously described,14 was 
calculated without the knowledge of participant’s clinical status. 
See online supplementary file for details. Briefly, peripheral 
blood mononuclear cells (PBMCs) were separated using density 
gradient method (Lymphoprep; Alere Technologies, Norway) 
from EDTA-anticoagulated blood. Total RNA purification kit 
(Norgen Biotek, Canada) was used followed by quantitative real-
time reverse transcriptase-PCR (qRT-PCR) using TaqMan assays 
(Applied Biosystems, Invitrogen) for the selected 30 ISGs.7 
These assays were performed using the BioMark HD System 
with appropriate cycling protocols for the 96.96 chip. Data were 
normalised using Peptidylprolyl isomerase A as a reference gene 
to calculate ΔCt.
Factor analysis was used to reduce the 30 ISGs into a 
smaller number of factors.26 Two factors, IFN-Score-A and 
IFN-Score-B, explained 84% of the variance with limited 
cross-loading. Factor scores were calculated as the median 
level of expression of the genes loaded by each factor.
skin biopsy
One 4 mm biopsy was obtained from non-lesional non-sun-ex-
posed areas (upper back or upper arms) of At-Risk individuals 
(n=10) and HCs (n=6), and from active lesions of patients with 
SLE (n=10). Biopsies were snap frozen in optimum cutting 
temperature (OCT) compound and sectioned at a thickness 
of 5 µm ensuring no remaining OCT material contaminating 
subsequent RNA extraction/RT procedures. Gene expression 
analysis and calculation of factor scores were conducted as for 
PBMCs.
statistical analyses
Associations between categorical variables were tested by Fish-
er’s exact and Stuart-Maxwell tests for independent and paired 
samples, respectively. Continuous variables were compared 
using either Student’s t-tests or analysis of variance (ANOVA) 
followed by pairwise Tukey tests. For associations, Kendall’s 
tau-b correlation was used if ties were present, otherwise using 
Pearson’s correlation. Receiver operator curves (ROCs) were 
used to assess predictive strength and identify optimal thresh-
olds for predicting progression to AI-CTD. For 13 At-Risk 
patients, gene expression data were missing at random due to 
samples not being processed on the day. For comparisons with 
HC and SLE groups, only At-Risk patients with complete data 
were presented. For prediction of progression, multiple impu-
tation by chained equations was used to create 20 complete 
datasets, results of which were combined according to Rubin’s 
rules. Multivariable analyses were performed using penalised 
logistic regression by Lasso method.27 Leave-one-out cross-val-
idation (R package  cv. glmnet)28 identified the largest penalty 
coefficient lambda within 1 SE of the value that minimised 
deviance in each imputed dataset; average coefficients from 
the best models were calculated. All analyses of IFN Scores 
were conducted using ΔCt scaling; results were then converted 
to relative expression (2−ΔCt) or fold difference (FD) (2−ΔΔCt).
Statistical analyses were performed using Stata V.13.1 
(StataCorp, College Station, Texas, USA), R V.3.3.329 and 
GraphPad Prism V.7.03 (GraphPad, La Jolla, California, USA) 
for Windows.
resulTs
Patient characteristics
The flowchart of participants is presented in figure 1. A total 
of 135 At-Risk individuals were recruited. Of these, 118 had 
at least 12 months of follow-up and were analysed. Baseline 
characteristics are described in table 1.
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Clinical outcomes at 12 months
At 12 months, 19/118 (16 %) At-Risk individuals progressed 
to a diagnosis of AI-CTD. These were SLE (n=14; 74%) and 
pSS (n=5; 26%). In those who progressed, all had one clin-
ical criterion at baseline. The number of clinical SLE criteria 
increased to 2 in 4/19 (21%), 3 in 9/19 (47%) and 4 in 6/19 
(32%) (Stuart-Maxwell χ2=20.0, p<0.001) at 12 months. These 
details are presented in table 2 and online supplementary figure 
S1. Two patients developed internal organ involvement; pleural 
effusion and class III lupus nephritis.
In contrast, 19/99 (19%) of the non-progressors had no clinical 
SLE criteria at both baseline and 12 months, 1/99 (1%) increased 
from 0 to 1, 41/99 (42%) decreased from 1 to 0 indicating a 
remission of autoimmunity and 38/99 (38%) had one criterion 
at both time points (Stuart-Maxwell χ2=38.1, p<0.001).
Notably, 1/99 (1%) of non-progressors had ankylosing spon-
dylitis while 4/99 (4%) of had cancers (lung=1, hepatocel-
lular=1, prostate=1 and leiomyosarcoma=1).
Interferon status in At-risk differs from sle
At baseline, IFN-Score-A differed between groups (ANOVA 
F=40.26; p<0.001). It was increased relative to HC (n=49) 
in both At-Risk (n=105; FD (95% CI) 2.21 (1.22 to 4.00), 
p=0.005) and SLE (n=114; 7.81 (4.33 to 14.04), p<0.001), 
and was increased in SLE relative to At-Risk (3.54 (2.22 to 5.63), 
p<0.001) (figure 2A). In contrast, although IFN-Score-B differed 
between groups overall (F=63.35; p<0.001), it did not differ 
between At-Risk and HC (0.98 (0.66 to 1.46), p=0.993), but 
was increased in SLE to both HC (3.85 (2.60 to 5.72), p<0.001) 
and At-Risk (3.93 (2.87 to 5.37), p<0.001) (figure 2B).
relationships of interferon scores with autoantibodies, 
complement and lymphopaenia
Correlations between routine immunology markers and IFN 
Scores were performed in observed data using reflected ΔCt so 
that higher IFN Scores represented greater expression. At base-
line, there was no association between number of positive ANA 
specificities (ie, anti-dsDNA, Ro, RNP etc.) and IFN-Score-A 
(n=105, Kendall’s tau-b 0.13, p=0.084) or IFN-Score-B (tau-b 
0.09, p=0.234) (figure 2C,D).
The titres of two antibodies that were mostly prevalent using 
Bioplex, anti-dsDNA and anti-Ro, were divided into three and 
two groups, respectively. There were no differences in both IFN 
Scores among the three anti-dsDNA groups (online supplemen-
tary figure S2A,B). Elevated levels of IFN-Score-A (FD 2.41 
(95% CI 1.10 to 5.26)) but not Score-B were found in the high 
titre, that is, ≥8 AI anti-Ro antibody positive group (online 
supplementary figure S2C, D).
There was a weak negative correlation between C4 levels and 
IFN-Score-A (n=97, Pearson’s r=−0.221, p=0.029) (figure 2E) 
but not IFN-Score-B (r=−0.089, p=0.385). There was a weak 
negative correlation between lymphocyte count and IFN-Score-A 
(n=105, r=−0.230, p=0.018) (figure 2F) but not IFN-Score-B 
(r=−0.127, p=0.195).
baseline interferon status in skin
In parallel to results obtained for PBMC, at baseline only 
IFN-Score-A was increased in non-lesional skin biopsies in 
At-Risk (n=10) versus HC (n=6); FD 28.74 (1.29 to 639.48), 
p=0.036. There was no difference in IFN-Score-B; FD 1.82 
(0.86 to 3.86), p=0.100. As expected, both IFN Scores were 
higher in SLE (active lesions) compared with either At-Risk or 
HC; all p<0.05.
Comparison of baseline interferon status between blood and 
skin
Expression of both IFN Scores was higher in At-Risk versus HC 
in both skin and PBMC, but FDs were greater in skin (figure 3C). 
This might have been due to the small sample size for skin 
samples (paired skin–PBMC samples were not available).
Prediction of AI-CTd using baseline interferon scores in blood
When At-Risk were divided according to AI-CTD progres-
sion status at 12 months, both IFN Scores differed among the 
groups overall (p<0.001) and both were elevated in At-Risk 
progressors (n=19) versus non-progressors (n=86), to a greater 
extent for IFN-Score-B (FD 3.22 (1.74 to 5.95), p<0.001) 
than IFN-Score-A (2.94 (1.14, 7.54), p=0.018) (figure 3A,B). 
Non-progressors did not differ from HC (n=49) for both scores; 
IFN-Score-B (0.79 (0.51 to 1.23), p=0.520) and IFN-Score-A 
(1.82 (0.93 to 3.53), p=0.096). Neither IFN Score differed 
between At-Risk progressors and SLE (both p>0.1).
Since the number of skin biopsies obtained in At-Risk was 
small (n=10), no formal association between IFN Scores and 
progression could be determined.
baseline IFn-score-b threshold of progression to AI-CTd
Prognostic ability of baseline IFN Scores to predict progression 
to AI-CTD at 12 months was assessed using ROC curve anal-
ysis. The area under the ROC curve was greater for IFN-Score-B 
(0.82 (95% CI 0.73 to 0.92)) than IFN-Score-A (0.70 (0.57 
to 0.83)); χ2=4.19, p=0.041. A cut-off of ≤5.01 ΔCt for 
IFN-Score-B maximised the Youden’s index (sensitivity+speci-
ficity−1) yielding 95% (95% CI 75% to 99%) sensitivity, 60% 
(50% to 70%) specificity, 35% (23% to 48%) positive predictive 
value (PPV) and 98% (90% to >99%) negative predictive value 
(NPV). However, for a rule-in biomarker for future prevention 
studies, a high specificity is required to exclude individuals with 
the lowest risk. For this purpose, we propose a cut-off of ≤3.90 
ΔCt that resulted in 68% (46% to 85%) sensitivity, 80% (70% 
to 88%) specificity, 43% (27% to 61%) PPV and 92% (84% to 
96%) NPV (figure 3D).
Table 2 Clinical characteristics of At-Risk progressors at 12 months
Clinical criteria
baseline 12 months
(n=19) (n=19)
Mucocutaneous
  ACLE or SCLE 5/19 (26%) 13/19 (68%)
  Mucosal ulcers 2/19 (11%) 8/19 (42%)
  Alopecia 0 4/19 (21%)
Musculoskeletal
  Synovitis 9/19 (47%) 18/19 (95%)
Haematological
  Leucopaenia or lymphopenia 3/19 (16%) 7/19 (37%)
  Thrombocytopenia 0 1/19 (5%)
Glandular signs 0 6/19 (32%)
Serositis
  Pleural effusion 0 1/19 (5%)
Renal
  Class III nephritis 0 1/19 (5%)
ACLE, acute cutaneous lupus erythematosus; SCLE, sub-acute cutaneous lupus 
erythematosus.
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baseline IFn scores were lower in At-risk without versus with 
one clinical criterion
All 20/118 (17%) At-Risk individuals who had no SLE clinical 
criterion at baseline did not progress to AI-CTD at 12 months. 
At baseline, FDs for both IFN scores differed among the groups 
overall (p<0.001) and both were lower in At-Risk with no 
criterion (n=17) versus with one criterion (n=88); all p<0.05 
(online supplementary figure S3 in the online supplementary 
file).
Figure 2 Pattern of baseline interferon scores and their relationships with clinical immunology markers. (A) Baseline expression of IFN-Score-A was 
higher in At-Risk individuals compared with healthy controls. (B) However, there was no difference in IFN-Score-B between both groups. ***Highly 
significant (p<0.001), **moderate significant (0.001<p<0.01), *significant (0.01<p<0.05). (C, D) Both IFN scores were not correlated with the 
number of positive antinuclear antibody (ANA) specificities (ie, sum of anti-dsDNA, Ro, La, Sm, Chromatin, RNP, Sm/RNP and Ribosomal P) and (E, 
F) there were only weak correlations between IFN-Score-A and complement and lymphocyte count. Data for gene expression were expressed as 
reflected values for ∆Ct so that higher IFN Scores represented greater expression.
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Musculoskeletal ultrasound
Of the 117 At-Risk individuals with ultrasound available, 21 
(18%) had ultrasound-defined synovitis at baseline (GS ≥2 
only=13, PD ≥1 with or without GS ≥2=8). Of the 20 individ-
uals who progressed, 7 (35%) had positive ultrasound at baseline 
versus 14% of non-progressors; p=0.050, PPV (95% CI)=33% 
(17% to 55%), NPV 86% (78% to 92%).
Furthermore, 43/118 of At-Risk individuals had clinical 
arthritis based on SLICC20 (8/43 (19%) had ≥2 joints with 
swelling or effusion while 35/43 (81%) had ≥2 joints with 
tenderness and early morning stiffness of ≥30 min) while 75/118 
had no arthritis. In those without arthritis, ultrasound-de-
fined synovitis was detected in 10/75 (13%) and 4/10 (40%) 
progressed to AI-CTD. Conversely, in those with arthritis, only 
11/42 (26%) had ultrasound-defined synovitis and 3/11 (27%) 
progressed to AI-CTD at 12 months. Sensitivity and specificity 
of physician-judged arthritis with ultrasound-defined synovitis 
were 52% and 68%, respectively.
Multivariable analysis of baseline predictors of progression 
to AI-CTd
In imputed univariable analyses, all putative predictors were 
associated with progression to AI-CTD at 12 months at the 
10% level of significance except for complement level and 
lymphocyte count (both p>0.1), which were excluded from 
multivariable analysis (table 3). In multivariable logistic 
regression, family history of ARDs (OR 8.20, p=0.012) and 
IFN-Score-B (OR=3.79, p=0.005) were independently associ-
ated with progression. Penalised ORs remained substantive for 
these variables when all other variables were removed from the 
model. Results in complete data (n=100) were similar (data not 
shown).
dIsCussIOn
In this study, we report a unique cohort of At-Risk of AI-CTD 
individuals with longitudinal follow-up until progression to clin-
ical autoimmunity. We demonstrate that IFN activity is strongly 
associated with progression independent of baseline clinical 
status, with measurement according to a two-score system we 
described being crucial. These results provide a rationale for 
diagnostic and preventative treatment pathways as well as assert 
the importance of interferons in disease initiation.
Referrals of ANA-positive individuals to rheumatologists has 
increased over the last decade.30 Concerns are that these At-Risk 
individuals may be discharged prematurely or be observed in an 
inefficient ‘watch and wait’ fashion until the diagnosis is clear, by 
which time the potential to prevent disease and confer the most 
benefit may be lost. Thus, by undertaking the largest prospective 
study of At-Risk individuals, which is the first to integrate clin-
ical, imaging and immunological assessments (including skin), 
Figure 3 Baseline interferon (IFN) scores in bloods as prognostic biomarkers. (A–B) Baseline expression of both IFN-Score-A and IFN-Score-B 
were higher in At-Risk individuals who progressed to autoimmune-related connective tissue disease compared with the non-progressors, but to a 
greater fold difference in the latter. ***Highly significant (p<0.001), **moderately significant (0.001<p<0.01), *significant (0.01<p<0.05). (C) Fold 
differences for both IFN scores between At-Risk and healthy controls (HCs) were greater in skin than bloods. (D) The area under the receiver operating 
characteristic curve was significantly greater for IFN-Score-B than IFN-Score-A. The blue arrow denotes the optimal cut-off using Youden’s index while 
the red arrow denotes the proposed cut-off for prevention study. PBMC, peripheral blood mononuclear cell; SLE, systemic lupus erythematosus.
 o
n
 4 February 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-213386 on 21 June 2018. Downloaded from
 
1437Md Yusof MY, et al. Ann Rheum Dis 2018;77:1432–1439. doi:10.1136/annrheumdis-2018-213386
Clinical and epidemiological research
our findings offer a novel approach, biomarkers and have impli-
cations for future development of targeted therapies for this 
group of patients.
Within ANA-positive individuals, different immune pheno-
types could be defined. At baseline, IFN-Score-A was elevated 
but not IFN-Score-B compared with HC. However, IFN-Score-B 
(and to a lesser degree, IFN-Score-A) were mostly elevated in 
those who progressed to AI-CTD. IFN-Score-A comprises many 
well-known ISGs that respond to IFN-I (IFN-α, IFN-β, IFN-κ, 
IFN-ω). In contrast, IFN-Score-B comprises ISGs that coincide 
with M3.4 and M5.12 modules of a previous microarray study.7 
These ISGs were suggested to be responsive to IFN-II (IFN-γ), 
IFN-III (IFN-λ) as well as IFN-I. However, we cannot exclude 
the influence of other inflammatory mediators on this pattern of 
gene expression.14 Some studies suggested that IFN-I contributes 
to priming cells to secrete IFN-II.31 32 Conversely, a study that 
measured IFN activity from serum postulated a sequential role 
of IFN-II augmentation that led to autoantibody accumulation 
and subsequent elevations in IFN-α prior to SLE.33 Although we 
could not confirm which IFN pathways predominate, our find-
ings suggest that progression to AI-CTD may not be exclusively 
driven by IFN-I but by a synergistic activation of ISGs induced 
by a range of IFNs and IFN-Score-B could act as a biomarker for 
more diverse immune activation.
At the tissue level, this is the first study that quantifies IFN 
activity in non-lesional skin of At-Risk individuals. Interestingly, 
similar patterns of immune dysregulation were shown between 
skin and PBMC. However, markedly greater FDs in both IFN 
scores were found in the former compared with the latter, thus 
highlighting skin as a potential site of AI-CTD initiation.
Only a third of the At-Risk individuals who had ultra-
sound-defined synovitis progressed to AI-CTD within 12 
months. Additionally, small numbers of asymptomatic patients 
with ultrasound-detected synovitis were identified, so further 
work is required to determine the role of ultrasound in assessing 
At-Risk individuals.
Together with a family history of ARD, IFN-Score-B from 
blood is independently predictive of progression and is conve-
nient as a biomarker. We have defined a cut-off level of 
IFN-Score-B with a moderate diagnostic accuracy in order to 
design a prevention study.
This study has some limitations. First, the cohort was 
recruited from secondary care as well as positive ANA detected 
by both Bioplex and indirect immunofluorescence, which might 
contribute to moderate-to-high pre-test probabilities for AI-CTD. 
Thus, our results might not be generalised to all ANA-positive 
cases in primary care setting. However, our cohort was quite 
heterogenous in terms of ethnicity and 17% of the patients 
had no SLE criterion at baseline. Second, we excluded individ-
uals with scleroderma or myositis-specific only autoantibodies, 
which might lead to preponderance of progression to SLE or 
pSS. Surprisingly, one patient had a severe ankylosing spondy-
litis and required biological therapy. Moreover, 4% of non-pro-
gressors had cancers thus highlighting the need to be vigilant of 
paraneoplastic manifestation in ANA-positive individuals as well 
as diverse alternative diagnoses in general. Lastly, sample size 
was still relatively small for multivariable analysis. However, we 
used penalised logistic regression to minimise overfitting of data.
In conclusion, a novel ISG score, IFN-Score-B and family 
history of ARD predict progression from ANA positivity to 
AI-CTD. After validation, the predictive value of IFN scores 
may allow us to identify patients with imminent AI-CTD for 
earlier intervention using therapies that block IFNs or conven-
tional immunosuppressants to avoid irreversible organ damage 
and glucocorticoid exposure. Additionally, patients with benign 
autoreactivity can be better identified.
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Table 3 Penalised logistic regression for predictors of progression to autoimmune-related connective tissue disease at 12 months
baseline predictors
no progression 
n=99 Progression n=19
univariable Or (95% CI),
p values
Multivariable Or (95% CI),
p values
Penalised 
coefficient to Or
Age, mean (SD) 49.0 (15.8) 39.6 (11.9) 0.96 (0.93 to 0.99), 0.016 0.97 (0.92 to 1.02), 0.232 0.000 to 1.000
Ever smoked, (%) 41.8% 20.0% 0.35 (0.11 to 1.12), 0.076 0.34 (0.06 to 1.91), 0.222 0.000 to 1.000
Family history of ARDs (%) 30.6% 65.0% 4.21 (1.53 to 11.61), 0.005 8.20 (1.58 to 42.53), 0.012 0.243 to 1.275
No of positive ANA specificities, median 
(IQR)
1 (1–1) 1 (1–2) 2.07 (0.97 to 4.40), 0.060 2.41 (0.71 to 8.20), 0.161 0.000 to 1.000
Complement C4 level, mean (SD) 0.29 (0.12) 0.26 (0.08) 0.06 (0.00 to 8.05), 0.264 Excluded Excluded
Lymphocyte count, mean (SD) 2.04 (0.77) 1.83 (0.67) 0.67 (0.34 to 1.34), 0.257 Excluded Excluded
No of joints with positive ultrasound for 
synovitis, median (IQR)
0 (0–0) 0 (0–2) 1.20 (0.97 to 1.47), 0.086 1.44 (0.98 to 2.11), 0.061 0.002 to 1.002
Patient VAS, median (IQR) 36 (16–61) 47 (26–75) 1.02 (1.00 to 1.04), 0.079 1.01 (0.98 to 1.04), 0.484 0.000 to 1.000
Physician VAS, median (IQR) 11 (3–31) 31 (15–47) 1.04 (1.01 to 1.06), 0.008 1.01 (0.97 to 1.06), 0.618 0.000 to 1.000
IFN-Score-A (−ΔCt), mean (SD)* −5.3 (1.9) −3.8 (2.26) 1.43 (1.11 to 1.84), 0.005 0.87 (0.54 to 1.39), 0.560 0.000 to 1.000
IFN-Score-B (−ΔCt), mean (SD)* −5.3 (1.4) −3.7 (1.0) 2.55 (1.60 to 4.08), <0.001 3.79 (1.50 to 9.58), 0.005 0.319 to 1.376
*Analysis was made based on reflected ∆Ct. Thus, the higher the number, the higher the gene expression to give positive values for ORs.
ANA, antinuclear antibody; ARD, autoimmune rheumatic disease; IFN, interferon; VAS, Visual Analogue Score.
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